Eli Lilly expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News ...

Eli Lilly & Co. expects to start selling its highly popular weight-loss drug in Hong Kong as early as the end of this year, ...

Eli Lilly (LLY) expects to start selling its weight-loss drug tirzepatide, branded as Mounjaro, in Hong Kong as early as the ...

Learn how to grow your wealth through smart investing strategies and financial planning in this informative article by a ...

Eli Lilly&Co. (NYSE:LLY) plans to start selling its popular weight-loss medication, Mounjaro, in Hong Kong by the end of this year, potentially becoming the first drug of its kind available in the ...

Eli Lilly said it sees fiscal year 2024 sales of $45.4 billion—$46 billion, compared to prior guidance of $45.4 billion—$46.6 ...

Eli Lilly to Introduce Mounjaro Weight-Loss Drug in Hong Kong by Year-End Global pharmaceutical giant Eli Lilly is gearing up ...

We recently compiled a list of the Jim Cramer’s Latest Game Plan: 20 Stocks to Watch. In this article, we are going to take a ...

Highlights,Eli Lilly, (NYSE:LLY),prepares to launch Mounjaro in Hong Kong by the end of the year.,Mounjaro is positioned to ...

There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it will receive a US$20 ...